MENU
Showcases Stock ranks Forex

Iteos Therapeutics Inc (ITOS)
13.64  0.47 (3.57%) 03-28 16:00
Open: 13.35 Pre. Close: 13.17
High: 13.7 Low: 12.83
Volume: 343,107 Market Cap: 489(M)
Stock Technical Analysis
Overall:     
Target: Six months: 16.00
One year: 18.69
Support: Support1: 11.33
Support2: 9.87
Resistance: Resistance1: 13.70
Resistance2: 16.00
Pivot: 11.60
Moving Averages: MA(5): 12.34
MA(20): 11.54
MA(100): 10.62
MA(250): 11.97
MACD: MACD(12,26): 0.48
Signal(12,26,9): 0.25
%K %D: %K(14,3): 94.67
%D(3): 78.47
RSI: RSI(14): 70.08
52-Week: High: 18.24
Low: 8.2
Change(%): 3.4
Average Vol(K): 3-Month: 268
10-Days: 283
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 13.701 - 13.749 13.749 - 13.793
Low: 12.698 - 12.757 12.757 - 12.811
Close: 13.542 - 13.628 13.628 - 13.707
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.

[ ITOS ] has closed above the upper band by 6.2%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 124.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
Company profile
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Stock chart
Stock News
Sat, 23 Mar 2024
iTeos Therapeutics, Inc. Revenue Breakdown – NASDAQ:ITOS – TradingView - TradingView

Sat, 23 Mar 2024
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Bought by Exchange Traded Concepts LLC - Defense World

Wed, 20 Mar 2024
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Short Interest Update - Defense World

Tue, 19 Mar 2024
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Sold by Citigroup Inc. - MarketBeat

Wed, 13 Mar 2024
ITOS Stock Quote Price and Forecast - CNN

Wed, 06 Mar 2024
iTeos Therapeutics expands board with industry veteran By Investing.com - Investing.com

Financial Analysis
Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Neutral
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M)
Shares Float (M) 35.84
% Held by Insiders 24790000.00
% Held by Institutions 0.54
Shares Short (K) 1730
Shares Short Prior Month (K)
Stock Financials
EPS -146680000.000
Book Value (p.s.)
Profit Margin
Operating Margin
Return on Assets (ttm) 171.7
Return on Equity (ttm) -13.0
Qtrly Rev. Growth 12600000.0
Gross Profit (p.s.) -86.957
Sales Per Share -15.817
EBITDA (p.s.)
Qtrly Earnings Growth -3.15
Operating Cash Flow (M)
Levered Free Cash Flow (M) -103.76
Stock Valuation
PE Ratio
PEG Ratio
Price to Book value
Price to Sales -0.86
Price to Cash Flow 0.98
Stock Dividends
Dividend
Dividend Yield
Dividend Growth 1800000.000

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android